ENTRY       D04540                      Drug
NAME        Insulin glulisine (USAN/INN);
            Insulin glulisine (genetical recombination) (JAN);
            Apidra (TN)
PRODUCT     INSULIN GLULISINE (sanofi-aventis U.S. LLC)
FORMULA     C258H384N64O78S6
EXACT_MASS  5818.6373
MOL_WEIGHT  5822.5816
SEQUENCE    (A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
            Gln Leu Glu Asn Tyr Cys Asn
            (B chain) Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala
            Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr
            (Disulfide bridge: A6-A11, A7-B7, A20-B19)
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG01636  Insulin preparation
              DG01796  Insulin analog, fast-acting
            Metabolizing enzyme inducer
             DG01637  CYP1A2 inducer
REMARK      Therapeutic category: 2492
            ATC code: A10AB06
            Product: D04540<JP/US>
EFFICACY    Antidiabetic, Insulin receptor agonist
  DISEASE   Diabetes mellitus [DS:H00408 H00409]
COMMENT     Insulin analog
            Treatment of type 1 and type 2 diabetes
TARGET      INSR (CD220) [HSA:3643] [KO:K04527]
  PATHWAY   hsa04910(3643)  Insulin signaling pathway
            hsa04930(3643)  Type II diabetes mellitus
INTERACTION CYP induction: CYP1A2 [HSA:1544]
STR_MAP     map07051  Antidiabetics
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10A INSULINS AND ANALOGUES
                A10AB Insulins and analogues for injection, fast-acting
                 A10AB06 Insulin glulisine
                  D04540  Insulin glulisine (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Insulins
               Insulin, Rapid-acting
                Insulin Glulisine
                 D04540  Insulin glulisine (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2492  Pancreatic hormones
                 D04540  Insulin glulisine (USAN/INN); Insulin glulisine (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG01636  Insulin preparation
               DG01796  Insulin analog, fast-acting
                D04540  Insulin glulisine
             Metabolizing enzyme inducer
              DG01637  CYP1A2 inducer
               D04540  Insulin glulisine
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01636  Insulin preparation
               D04540  Insulin glulisine
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               INSR family
                INSR (CD220)
                 D04540  Insulin glulisine (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04540
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04540
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04540
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04540
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D04540
DBLINKS     CAS: 207748-29-6
            PubChem: 47206386
///
